According to research, when Aviptadil is dissolved in saline, it shows uncertain stability properties that result in significant pharmaceutical supply and use challenges. The exploration and development of a novel RLF-100 formulation appear to be more stable at the temperatures used for shipping and long-term storage.
The chairman and board of directors at Relief therapeutics state that this new and stable potential formation of RLF-100 is to be delivered by using multiple routes of administration for the treatment of multiple serious diseases, including lung diseases and other major disorders.
According to the previous reports, Relief intended to initiate a phase 2b dose after a ranging study in 72 patients suffering from pulmonary sarcoidosis using the inhaled RLF-100. Along with the administration of 12 weeks, many patients will have the option to participate in the extension phase as decided in the meeting with the United States.
Moreover, the food and drug administration (FDA) is planning to confirm the efficacy and security endpoints of the proposed dosing regime. It is based on a positive outcome, and the trial is expected to start in 2023.
About RLF-100:
RLF0-100 is also known as Aviptadil. It is a synthetic form of a vasoactive intestinal peptide consisting of 28 amino acids. It was first discovered in 1970. Although, it was first identified in the human intestinal track, where it is known to produce concentrations primarily in the lungs. Also, it shows a multimodal mechanism of action.
Specifically, it reduces the release of inflammatory cytokines and leads to the prevention of cytokine storm syndrome and viral replication. Moreover, it reduces the effect of immunomodulation, vasodilating, and broncho-dilating. Almost 70 percent of VIP in the human body is bound to a less common type of cell in the lung with the 2 type of cells that helps in the transmission of oxygen to the whole body.
It is under development for the prevention and cure of several acute as well s chronic lung diseases. It was granted an Orphan Drug Designation by FDA. More samples of it are exported for the treatment of checkpoint inhibitor-induced pneumonitis. Moreover, RLF-100 is also used to evaluate COVID-19-related diseases.
This company is also planning to conduct the European proof o concept in the clinical development of this medicine. Hence, it will be used in the treatment of chronic berylliosis, for which there are no approved treatments.
About Relief Therapeutics Holding SA:
It is a legal organization that deals in the production of multiple therapeutic products based on the cynical stage programs. Relief therapeutics is engaged in testing and using newly produced medicines for strong scientific rationale.
It presents its outstanding shares under the name of RLFTF Stock. The company was established in 2013. The head office is established in Geneva, Switzerland.
Relief also continues to study Aviptadil for several possible lung-related conditions. Finally, Relief’s 2021 acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH brought to Relief a diverse pipeline of marketed and development-stage programs.
About RLFTF Stock:
This stock is holding the current price of 0.036 US dollars. The maximum price for RLFTF Stock in the previous five years was 0.62 US dollars on August 7, 2020. It holds the minimum price of 0.030 US dollars on June 10, 2020.
However, Relief Therapeutics is performing its operations well, and the total forecasted revenue rate is 53.2%.
OTC Wiki 
Leave a comment